Evidence map›Paper›PMID 42091592›Full record

ArticleNature communications2026

CD248 acts as a mechanosensory switch in fibroblast subsets to establish distinct pathological niches in renal fibrosis.

Chao Xu, Shaojie Liu, Yike Zhou, Fa Yang, Zhengxuan Li, Kai Gan, Yu Li, Keying Zhang, Tong Lu, Hongtao Song and 11 more

Abstract read
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Chao Xu *Department of Urology, Xijing Hospital, The Fourth Military Medical University, Xi'an, China.
Shaojie Liu *Department of Urology, Xijing Hospital, The Fourth Military Medical University, Xi'an, China.
Yike Zhou *Department of Urology, Xijing Hospital, The Fourth Military Medical University, Xi'an, China.
Fa Yang *Department of Urology, Xijing Hospital, The Fourth Military Medical University, Xi'an, China.
Zhengxuan LiDepartment of Urology, Xijing Hospital, The Fourth Military Medical University, Xi'an, China.
Kai GanDepartment of Urology, Xijing Hospital, The Fourth Military Medical University, Xi'an, China.
Yu LiDepartment of Urology, Daping Hospital, Army Medical University, Chongqing, China.
Keying ZhangDepartment of Urology, Xijing Hospital, The Fourth Military Medical University, Xi'an, China.
Tong LuDepartment of Urology, Xijing Hospital, The Fourth Military Medical University, Xi'an, China.
Hongtao SongDepartment of Urology, Xijing Hospital, The Fourth Military Medical University, Xi'an, China.
Jun JiangDepartment of Urology, Xijing Hospital, The Fourth Military Medical University, Xi'an, China.ORCID http://orcid.org/0000-0002-5971-3174
Jiayang QinWest China School of Medicine, West China Hospital, Chengdu, China.
Zhihao HuDepartment of Urology, Xijing Hospital, The Fourth Military Medical University, Xi'an, China.
Ruochen QiDepartment of Urology, Xijing Hospital, The Fourth Military Medical University, Xi'an, China.
Shuaijun MaDepartment of Urology, Xijing Hospital, The Fourth Military Medical University, Xi'an, China.
Changhong ShiDivision of Cancer Biology, Laboratory Animal Center, The Fourth Military Medical University, Xi'an, China.
Rui ZhangDepartment of Immunology, State Key Laboratory of Cancer Biology, The Fourth Military Medical University, Xi'an, China.ORCID http://orcid.org/0000-0002-6147-1573
Dailing SiMilitary Medical Innovation Center, The Fourth Military Medical University, Xi'an, Shaanxi, China.
Weihong WenSchool of Life Sciences and Technology, Northwestern Polytechnical University, Xi'an, China. weihongwen@nwpu.edu.cn.
Donghui HanDepartment of Urology, Xijing Hospital, The Fourth Military Medical University, Xi'an, China. 906812205@qq.com.
Weijun QinDepartment of Urology, Xijing Hospital, The Fourth Military Medical University, Xi'an, China. qinwj@fmmu.edu.cn.ORCID http://orcid.org/0000-0002-7509-7164

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although the heterogeneity and plasticity of fibroblasts are recognized hallmarks of tissue fibrosis, their specific contributions to renal fibrosis progression and the therapeutic validity of targeting key effector subsets remain key unanswered questions. Here, we revealed that diverse, functionally exclusive fibroblast subpopulations actively shape their local microenvironment. Pro-inflammatory fibroblasts (i-Fibs) construct immune-active areas, while pro-fibrotic fibroblasts (ECM-Fibs) generate fibrogenic zones. These two distinct microenvironments form a spatial mosaic, occupying mutually exclusive territories within the kidney tissue. We identified mechanotransduction as a signal governing the switch from i-Fibs to the pathogenic ECM-Fib phenotype. Through unbiased bioinformatics and genetic tools, we pinpointed CD248 as a specific cell-surface protein on this matrix-producing subset. Mechanistically, CD248, via its C-type lectin-like domain, senses the disordered matrix, promoting focal adhesion assembly and YAP nuclear translocation through an IQGAP1/ARF6-GTP-dependent axis, leading to a sustained feedback loop between aberrant matrix and myofibroblasts activation. A monoclonal antibody targeting CD248, IgG78, effectively interrupted this feedback loop, mitigating fibrogenesis both in vitro and in vivo in male mice. Collectively, this study established that fibroblast heterogeneity drives pathological niche specification in the fibrotic kidney and validated CD248 as a promising therapeutic target to counteract tissue fibrosis by disrupting aberrant mechanosignaling.

Indexed as

Antigens, CDFibroblastsKidneyKidney DiseasesMechanotransduction, CellularAnimalsExtracellular MatrixFibrosisHumansMaleMiceMice, Inbred C57BLMyofibroblastsAntigens, CD

Identifiers

PMID42091592
PMCPMC13402351

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.